Inspections, Compliance, Enforcement, and Criminal Investigations
Aino Co., Ltd. of North China Pharmaceutical Group - Close Out Letter 12/14/12
Department of Health and Human Services
|Food and Drug Administration|
Silver Spring, MD 20993
December 14, 2012
Mr. Hanson Wu
Aino Co., Ltd. of North China Pharmaceutical Group
31 Xingye Street, Economic & Technical Development Zone
Shijiazhuang, Hebei, China 052165
Dear Mr. Wu,
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter# 300-12-014 dated August 30, 2012. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Deputy Director for Policy and Analysis
Office of Compliance
Center for Drug Evaluation and Research